Pharmaceutical News

RSS

French defend drug after patients develop liver problems

Health authorities in the U.S. are recommending that doctors keep a close eye on patients taking Ketek for signs of liver problems and to stop treatment if symptoms develop.

24 Jan 2006

Injection of EU funds for a microdose project

A new EU-funded project kicked off this month which aims to bridge the gap between the laboratory and the clinic. The EU Microdose AMS Partnership Programme (EUMAPP) aims to boost Europe’s expertise in micodosing and its application of AMS, or accelerator mass spectrometry, to developing new candidate drugs for treating diseases the world over.

23 Jan 2006

Statins account for 81% of first-line therapies for dyslipidemia treatment

Decision Resources, Inc., finds that despite the dominant market position of statins in the treatment of dyslipidemia, only 81% of patients receive a statin as a first-line therapy for the disease.

23 Jan 2006

Bristol-Myers Squibb agrees to record securities litigation settlement with sweeping drug disclosure requirements announces Labaton Sucharow

After prosecuting the securities litigation claims against Bristol-Myers Squibb Co. (BMS) for over five years, Labaton Sucharow, Lead Counsel representing the class and Lead Plaintiff, the LongView Collective Investment Fund of the Amalgamated Bank, reached an agreement in principle to settle the claims for $185 million in addition to meaningful corporate governance reforms that will affect future consumers and investors alike.

23 Jan 2006

American Academy of Dermatology disagrees with eczema medication action taken by FDA

The American Academy of Dermatology (Academy) has issued a statement in response to the U.S. Food and Drug Administration’s (FDA) announcement that a black box warning will be added to the labeling and a medication guide will be distributed for the topical calcineurin inhibitors (TCIs), pimecrolimus and tacrolimus.

23 Jan 2006

FDA fast track status for Alfimeprase

Nuvelo Inc. today announced that it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its lead product candidate, alfimeprase, for the treatment of acute peripheral arterial occlusion (PAO), or "leg attack."

23 Jan 2006

New version of diet drug not suitable for some

According to the U.S. Food and Drug Administration a version of the diet drug Xenical, which will be available without a prescription, may be not be suitable for some people.

23 Jan 2006

Mylan announces tentative approval for Rabeprazole sodium delayed-release tablets

Mylan Laboratories Inc. has announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Rabeprazole Sodium Delayed-release Tablets, 20 mg.

23 Jan 2006

Novel compound stops brain cell degeneration in Alzheimer's disease

Drug discovery researchers at Northwestern University have developed a novel orally administered compound specifically targeted to suppress brain cell inflammation and neuron loss associated with Alzheimer's disease.

22 Jan 2006

Black box warnings for two eczema creams

Food and Drug Administration officials in the U.S. have announced that two prescription creams to treat eczema will now carry strong warnings about the possible risk of skin cancer, lymphoma and other cancers.

22 Jan 2006

Danger of resistance to malaria drug

The World Health Organization (WHO) has issued new guidelines concerning the use of the malaria drug Artemisinin.

22 Jan 2006

Argentina and Brazil join forces to produce AIDS drugs

Argentina's Health Ministry has announced that in partnership with the Brazilian government they plan to produce their own anti-AIDS drugs in an effort to lower the cost of treatment.

19 Jan 2006

FDA unpopular over label liability revamp

The Food and Drug Administration in the U.S. has said that federally approved drug labels pre-empt state liability laws and are part of a revamp of the lengthy, hard-to-read instructions that come with medicines.

19 Jan 2006

Galapagos and Cancer Research Technology announce new anti-cancer drug discovery collaboration

Galapagos NV and Cancer Research Technology ("CRT"), specialists in oncology drug discovery and commercialization, a wholly owned company of Cancer Research UK, announced today that they have entered into a new collaboration in anti-cancer drug discovery research.

19 Jan 2006

Caretek Medical signs feasibility agreement with major pharma for protein based drug

Caretek Medical Ltd, an Oxford-based company developing an innovative needle-free drug delivery system, today announced that it has signed a feasibility study agreement with a major global pharmaceutical company.

19 Jan 2006

Vioxx may still be the best option for treating some forms of arthritis

Scientists believe that despite the current concerns around anti-inflammatory drugs like Vioxx, they may still be the best option for treating some forms of arthritis.

18 Jan 2006

Hopes dashed for peanut allergy drug Xolair

Hopes have been dashed for a potential treatment for peanut allergies following the severe reactions suffered by two children during a clinical trial.

18 Jan 2006

Anti-Obesity diet drug from cannabis works!

For those whose New Year's resolution was to yet again try to lose those extra kilos help may be at hand in the form of a new wonder drug derived from cannabis.

17 Jan 2006

FDA warns against buying prescription drugs on the net or overseas

According to the U.S. Food and Drug Administration (FDA), consumers and healthcare professionals who fill out their prescriptions abroad are putting themselves at risk.

17 Jan 2006

Drug discovery companies turn to low-cost Asian countries to evade stringent regulations

The Indian and Chinese drug discovery outsourcing market is riding a crest with companies from outside Asia increasingly seeking to outsource drug discovery to these countries for greater cost savings. Other major factors driving this shift to Indian and Chinese companies are the better access to expertise, productivity gains, process improvements, variable costs, avoidance of capital outlays and opportunities for companies to focus on specific niches.

16 Jan 2006